Evidence map›Paper›PMID 39822359›Full record

ArticleGland surgery2024

Propensity analysis reveals survival disparities between T1a and T1b well-differentiated thyroid cancer based on surgery.

Madeleine B Landau, Mohammad H Hussein, Marcela Herrera, Joshua Linhuber, Eman Toraih, Emad Kandil

Abstract read
In one paragraph

Article in Gland surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Madeleine B LandauSchool of Medicine, Tulane University, New Orleans, LA, USA.ORCID https://orcid.org/0009-0007-7315-8326
Mohammad H HusseinDivision of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA, USA.
Marcela HerreraSchool of Medicine, Tulane University, New Orleans, LA, USA.
Joshua LinhuberSchool of Medicine, Tulane University, New Orleans, LA, USA.
Eman ToraihDivision of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA, USA.
Emad KandilDivision of Endocrine and Oncologic Surgery, Department of Surgery, School of Medicine, Tulane University, New Orleans, LA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: With rising well-differentiated thyroid cancer (WDTC) incidence, the appropriate treatment choice remains controversial for T1 tumors <2 cm. This study analyzed differences in surgery refusal and survival outcomes between T1a (<1 cm) and T1b (1-2 cm) WDTC, examining the demographic and clinical characteristics associated with patients who decide to either undergo or refuse recommended surgery. Methods: We studied 81,664 T1N0M0 WDTC patients in the Surveillance, Epidemiology, and End Results (SEER) registry [2000-2019]. Treatment with surgery (n=81,565) or refusal (n=99) was compared. Propensity score matching balanced groups. Cox models assessed mortality predictors. Results: Among 81,664 patients, the overall mortality rate was 5.7% (n=4,635 deaths). Refused surgery associated with higher mortality (11.1% Conclusions: Our study reveals notable differences in survival and mortality between T1a and T1b WDTC, underscoring the need for subtype-specific, evidence-based treatment guidelines. For T1b patients, surgery remains the standard of care with significant improvements in outcomes. In contrast, select T1a patients may benefit from active surveillance, offering comparable survival rates while potentially enhancing quality of life.

Indexed as

personalized medicinesurgerysurvivalThyroid cancertreatment

Identifiers

PMID39822359
PMCPMC11733632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.